Cancer Chemotherapy and Pharmacology

, Volume 65, Issue 3, pp 503–508

Multicenter phase 2 study of induction chemotherapy with docetaxel and nedaplatin for oral squamous cell carcinoma

Authors

    • Department of Dentistry and Oral SurgeryShinshu University School of Medicine
  • Etsuhide Yamamoto
    • Department of Oral and Maxillofacial SurgeryKanazawa University Graduate School of Medical Science
  • Shinichi Nozaki
    • Department of Oral and Maxillofacial SurgeryNational Hospital Organization Kanazawa Medical Center
  • Shigehito Wada
    • Department of Oral and Maxillofacial Surgery, Faculty of MedicineUniversity of Toyama
  • Isao Furuta
    • Department of Oral and Maxillofacial Surgery, Faculty of MedicineUniversity of Toyama
  • Masaru Miyata
    • Department of Oral and Maxillofacial SurgeryIshikawa Prefectural Center Hospital
  • Kenji Kurashina
    • Department of Dentistry and Oral SurgeryShinshu University School of Medicine
Original Article

DOI: 10.1007/s00280-009-1056-z

Cite this article as:
Kurita, H., Yamamoto, E., Nozaki, S. et al. Cancer Chemother Pharmacol (2010) 65: 503. doi:10.1007/s00280-009-1056-z

Abstract

Purpose

To determine the clinical and hisotological efficacy and toxicities of induction chemotherapy with docetaxel (DOC) and nedaplatin (CDGP) for oral squamous cell carcinoma (OSCC) in the preoperative setting.

Methods

A total of 30 patients with locally advanced but operable OSCC were enrolled. Combination induction chemotherapy consisted of DOC 60 mg/m2 followed by CDGP 100 mg/m2.

Results

All patients received one cycle of chemotherapy. In the clinical assessment, ten patients achieved partial response for an overall response rate of 33.3% (95% CI, 16.4–50.2%). Histological assessment of surgical specimens showed an overall response rate of 56.6% (95% CI, 38.9–74.3%). Although severe neutropenia was observed in 90% of patients, only one patient (3.3%) experienced severe infection. Toxicities associated with this regimen did not interfere with planned radical surgery.

Conclusions

A single cycle of preoperative combination chemotherapy with DOC and CDGP showed moderate histological activity with an acceptable safety profile for the planned radical surgery. Further studies testing more cycles before surgery might be more appropriate.

Keywords

Neoadjuvant chemotherapySquamous cell carcinomaDocetaxelNedaplatinOral cancer

Copyright information

© Springer-Verlag 2009